Indeed, IL-6 and IDO have been linked to poor treatment outcomes, tumor recurrence, and aggressive tumor progression in breast cancer (49), nasopharyngeal carcinoma (50), and prostate cancer (51) patients. The gene discussed is IL6; the disease is prostate cancer.